

How to Acquire VYEPTI® (eptinezumab-jjmr)

VYEPTI is the first and only intravenous calcitonin gene-related peptide antagonist (IV anti-CGRP) indicated for the preventive treatment of migraine in adults. VYEPTI is given as just one 30-minute IV treatment every 3 months.

VYEPTI National Drug Code

10-Digit Format	11-Digit Format for Claims Submission	HCPCS J-Code
100 mg/mL Solution in Single-dose Vial		
67386-130-51	67386-0130-51	J3032

Order Through One of the Following:

Authorized Specialty Distributors

ASD Healthcare	Besse Medical	McKesson Plasma & Biologics
P: 800-746-6273 F: 800-547-9413	P: 800-543-2111 F: 800-543-8695	P: 877-625-2566 F: 888-752-7626
McKesson Specialty Care Division	Oncology Supply	
P: 855-477-9800 F: 800-800-5673	P: 800-633-7555 F: 800-248-8205	

Authorized Specialty Pharmacies

Orsini Healthcare	AllianceRx Walgreens Prime
P: 800-259-7145 F: 877-892-3019 orsinihealthcare.com/enrollment-forms	P: 855-244-2555 F: 877-828-3939 alliancerxwp.com/referral-forms

Lundbeck does not recommend the use of any particular specialty distributor or specialty pharmacy.

Specialty Pharmacy Checklist When Submitting a Prescription

- Either complete the specialty pharmacy enrollment form, OR send the prescription via fax or electronic medical record. For Home Infusion, please complete the Orsini VYEPTI Patient Enrollment Form or contact your Home Infusion provider directly.
- Include patient demographics, active medical and pharmacy insurance information, and any clinical information on file
- List the J-code for VYEPTI (J3032) and the specialty pharmacy's name as the service provider
- Specify if your office has secured a Prior Authorization prior to sending the prescription to the specialty pharmacy

**For assistance with reimbursement questions,
contact a Lundbeck Field Reimbursement Specialist.**

See the next page for information on infusion location options.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Please see additional Important Safety Information on the next page.
For more information, see the Full [Prescribing Information](#),
including [Patient Information](#), or visit vyeptihcp.com.


VYEPTI®
(eptinezumab-jjmr)
100 mg/mL Injection for IV

Infusion Locations

VYEPTI® (eptinezumab-jjmr) Can be Administered in Several Different Settings



Healthcare provider office

A healthcare provider's office that is equipped with the resources to provide infusion therapy in the office setting.



Stand-alone infusion center

An independent infusion center which may be part of a national or regional chain, provides flexible scheduling and may have additional amenities such as, private suites, WiFi, TV, and snacks.



Hospital-owned outpatient center/clinic

Usually part of a local hospital or health system organization and may have similar features as stand-alone infusion centers.



VYEPTI Home Infusion*

Provides services in all 50 states and provides home health nurses that visit patients in their home or other location as needed (ie, home, work, school, vacation).

If you do not have a preferred infusion location for a patient, please refer to the VYEPTI Infusion Locator at vyeptihcp.com/resources-vyepti-locator to find a list of options.

When Selecting an Infusion Location for a Patient, Consider the Following:

- Does the infusion location accept the patient's insurance?
- Is VYEPTI covered for that specific infusion location?
- How far is the infusion location from the patient's residence or desired location?
- Has the infusion location worked with VYEPTI before?
- How does the infusion location communicate with the office?

*If choosing Home Infusion, you may complete the Orsini VYEPTI Patient Enrollment Form, which can be found at orsinihealthcare.com/enrollment-forms. Fax the completed and signed form to Orsini at 877-892-3019. Other Home Infusion provider options may be available. Contact your Home Infusion provider for more information.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 2\%$ and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the [Full Prescribing Information](#), including [Patient Information](#), or visit vyeptihcp.com.

